This press release is being
disseminated as required by the early warning requirements of applicable
Canadian securities laws. Paul Averback MD of 9900 Cavendish Blvd. Suite 306,
St-Laurent, Quebec, announces today that he has sold in a private transaction
for financial planning purposes 465,000 common shares of Nymox Pharmaceutical
Corporation NYMX for a total consideration of $2,032,092 ($1,999,500 US).
The sale represents approximately 1.38 % of the shares of Nymox issued and
outstanding. Dr. Averback has no further intention to acquire or sell
securities of the Corporation at this time. As a result of this sale, Dr.
Averback continues to own and control 11,774,914 shares of Nymox or
approximately 34.9 % of the shares of Nymox issued and outstanding. An
additional 607,031 shares of Nymox (approximately 1.8 %) are owned by a family
trust of which Dr. Averback is a trustee. Dr. Averback is subject to the early
warning requirements for this transaction because he is a control person of
Nymox by virtue of the fact that he owns more than 20% of the outstanding
shares of Nymox. The sale relies on the prospectus exemption contained in
Section 2.3 of Regulation 45-106 - Prospectus and Registration Exemptions.
Nymox's common shares are listed on the NASDAQ Exchange under the symbol
"NYMX".
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in